Twist Bioscience Corporation: Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2
Twist Bioscience Corporation: Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2 -- Controls to be Used to Develop, Verify and Validate Tests that Identify More Transmissible Variant -- Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating i...
South Africa United Kingdom Emilym Leproust Facebook Linkedin Youtube Exchange Commission On European Centers For Disease
Source: finanznachrichten.de